Gastroenterology Research and Practice

Review Article

Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis

Table 3

Characteristics of included studies of lymphoma in IBD.
(a)
AuthorJournalPublication yearStudy designStudy populationRegion of originNumber of sitesStudy duration (yrs)Person-yearsNumber of patientsDiagnosisMean age (yrs)Female (%)Mean disease duration (yrs)Surgery (%)
Abbas et al. [40]Am J Gastroenterol2012CohortNational registryUnited StatesCountrywide11.0 352,429 32,039 UC60.07.0  
Beaugerie et al. [41]Lancet2009CohortNational registryEurope (Western)Countrywide3.0 22,706  
10,899  
11,807 		10,810  
5,153  
5,657 		IBD 
CD 
UC		 53.0  
Bernstein et al. [24]Cancer2001Case-controlAdministrative claimsCanadaRegionwide14.0 41,005  
21,340  
19,665 		5,529  
2,857  
2,672 		IBD 
CD 
UC		39.0 
36.3 
41.7		54.5 
59.0 
50.0		  
Chiorean et al. [42]Dig Dis Sci2011Case-controlReferral centerUnited States18.4 30,121  
19,127  
10,994 		3,585  
2,277  
1,308 		IBD 
CD 
UC		    
Farrell et al. [26]Gut2000CohortReferral centerEurope (Western)19.0 6,256 782 IBD44.152.010.0 
Fraser et al. [18]Aliment Pharmacol Ther2002CohortReferral centerEurope (Western)Countrywide35.0 55,388  
20,494  
34,894 		1,578  
584  
994 		IBD 
CD 
UC		35.053.0  
Herrinton et al. [43]Am J Gastroenterol2011CohortAdministrative claimsUnited StatesRegionwide13.0 67,867 16,023 IBD 53.0  
Jess et al. [8]Am J Gastroenterol2013CohortRegional registryEurope (Western)132.0 33,843  
11,261  
22,582 		2,211  
774  
1,437 		IBD 
CD 
UC		 53.0 
57.0 
49.0		  
Jess et al. [39]Aliment Pharmacol Ther2004CohortRegional registryEurope (Western)Regionwide35.06,569374CD 58.0  
Jussila et al. [10]Scand J Gastroenterol2013CohortNational registryEurope (Western)Countrywide23.0232,536 
51,876  
180,660 		20,970  
4,983  
15,987 		IBD 
CD 
UC		    
Khan et al. [44]Gastroenterology2013CohortNational registryUnited StatesCountrywide10.0 199,046 36,891 UC60.07.0  
Lakatos et al. [45]J Crohn’s Colitis 2012CohortProvincial registryEurope (Eastern)731.0 19,293  
7,093  
12,830 		1,420  
506  
914 		IBD 
CD 
UC		32.5 
28.5 
36.5		48.8 
50.0 
47.6		 22.8 
41.3 
4.2
Lewis et al. [46]Gastroenterology2001CohortNational registryEurope (Western)Countrywide9.0 64,239  
24,221  
40,018 		16,996  
6,605  
10,391 		IBD 
CD 
UC		47.3 
44.3 
50.3		54.0 
58.0 
50.0		  
Loftus Jr. et al. [47]Am J Gastroenterol2000CohortRegional registryUnited States253.0 6,662  
3,150  
3,512 		454  
216  
238 		IBD 
CD 
UC		 24.014.9
Mellemkjær et al. [33]Cancer Causes Control2000CohortNational registryEurope (Western)Countrywide16.0 22,875 2,645 CD 50.0  
Mizushima et al. [21]Digestion2010CohortReferral centerAsia120.0 4,248 294 CD39.030.6  
Palli et al. [22]Gastroenterology2000CohortRegional registryEurope (Western)119.0 10,592  
2,716  
7,877 		920  
231  
689 		IBD 
CD 
UC		    
Pasternak et al. [34]Am J Epidemiology2013CohortNational registryEurope (Western)Countrywide11.0 304,992 38,772 IBD47.055.0 4.0
Van Domselaar et al. [48]J Gastroenterol Hepatol2010CohortReferral centerEurope (Western)1  8,563 911 IBD53.028.64.8 
Winther et al. [19]Clin Gastroenterol Hepatol2004CohortRegional registryEurope (Western)Regionwide35.0 22,290 1,160 UC 53.4  
Yano et al. [14]J Gastroenterol Hepatol2013CohortReferral centerAsia125.0 10,552 770 CD25.131.313.1 
(b)
AuthorJournalPublication yearPSC (%)Pancolitis (%)Immunomodulator use (%)Biologic use (%)Observed number of lymphomasIncidence rate (per 100,000 persons)Standard error95% CI lower bound95% CI upper boundBias rating
Abbas et al. [40]Am J Gastroenterol2012  0.00.028280.04.870.789.3Moderate
Beaugerie et al. [41]Lancet2009 29.6 
13.0 
16.0		0.0 
0.0 
0.0		0.0 
0.0 
0.0		6 
3 
3		26.4 
27.5 
25.4		10.8 
15.9 
14.7		5.3 
−3.6 
−3.3		47.5 
58.6 
54.1		Moderate
Bernstein et al. [24]Cancer2001  0.0 
0.0 
0.0		0.0 
0.0 
0.0		16 
9 
7		39.0 
42.2 
35.6		9.8 
14.1 
13.5		19.9 
14.6 
9.2		58.1 
69.8 
62.0		Moderate
Chiorean et al. [42]Dig Dis Sci2011    8 
5 
3		26.6 
26.1 
27.3		9.4 
11.7 
15.8		8.2 
3.2 
−3.6		45.0 
49.0 
58.2		Moderate
Farrell et al. [26]Gut2000 26.030.0 464.032.01.3126.7Moderate
Fraser et al. [18]Aliment Pharmacol Ther2002 30.00.0 
0.0 
0.0		0.0 
0.0 
0.0		5 
1 
4		9.0 
4.87 
11.5		4.0 
4.9 
5.8		1.1 
−4.7 
0.2		16.9 
14.4 
22.8		Moderate
Herrinton et al. [43]Am J Gastroenterol2011  0.00.03348.68.532.065.2Moderate
Jess et al. [8]Am J Gastroenterol2013 26.7 
41.0 
19.0		27.2 
45.0 
18.0		 15 
7 
8		44.3 
62.2 
35.4		11.4 
23.5 
12.5		21.9 
16.1 
10.9		66.7 
108.3 
59.9		Moderate
Jess et al. [39]Aliment Pharmacol Ther2004    00.0 0.03.7Moderate
Jussila et al. [10]Scand J Gastroenterol2013    72 
14 
58		31.0 
27.0 
32.1		3.7 
7.2 
4.2		23.8 
12.9 
23.8		38.2 
41.1 
40.4		Moderate
Khan et al. [44]Gastroenterology2013  0.00.011960.05.549.270.8Moderate
Lakatos et al. [45]J Crohn’s Colitis20122.3 
1.8 
2.7		30.2 
35.9 
24.4		0.0 
0.0 
0.0		0.0 
0.0 
0.0		3 
1 
2		15.5 
14.1 
15.6		8.9 
14.1 
11.0		−2.0 
−13.5 
−6.0		33.0 
41.7 
37.2		Moderate
Lewis et al. [46]Gastroenterology2001  9.5 
13.0 
6.0		 18 
7 
11		28.0 
28.9 
27.5		6.6 
10.9 
8.3		15.1 
7.5 
11.2		40.9 
50.3 
43.8		Moderate
Loftus Jr. et al. [47]Am J Gastroenterol2000    1 
1 
0		15.0 
32.0 
0.0		15.0 
32.0 
 		−14.4 
−30.7 
0.0		44.4 
94.7 
3.7		Moderate
Mellemkjær et al. [33]Cancer Causes Control2000    417.58.80.434.7Moderate
Mizushima et al. [21]Digestion2010 12.4  00.0 0.03.7Moderate
Palli et al. [22]Gastroenterology2000    7 
1 
6		66.0 
36.8 
76.2		24.9 
36.8 
31.1		17.1 
−35.3 
15.2		114.9 
108.9 
137.2		Moderate
Pasternak et al. [34]Am J Epidemiology2013  0.00.04615.12.210.719.5Moderate
Van Domselaar et al. [48]J Gastroenterol Hepatol2010    781.730.921.2142.2Moderate
Winther et al. [19]Clin Gastroenterol Hepatol2004 54.0  217.912.7−6.942.8Moderate
Yano et al. [14]J Gastroenterol Hepatol2013 14.7  00.0 0.03.7Moderate
Did not report separate incidence estimates for CD and UC.